We are live on ! Find out more

Drug Manufacturers - General
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
LLY icon
1
Eli Lilly
LLY
$1.04T
$1.04T $1,169.60 1.61%
JNJ icon
2
Johnson & Johnson
JNJ
$618B
$618B $256.48 0.76%
ABBV icon
3
AbbVie
ABBV
$481B
$481B $272.42 0.39%
MRK icon
4
Merck
MRK
$351B
$351B $142.38 0.29%
NVS icon
5
Novartis
NVS
$272B
$272B $143.11 0.12%
AZN icon
6
AstraZeneca
AZN
$246B
$246B $158.78 0.84%
AMGN icon
7
Amgen
AMGN
$220B
$220B $407.44 1.37%
GILD icon
8
Gilead Sciences
GILD
$182B
$182B $147.10 0.17%
NVO
9
Novo Nordisk
NVO
$169B
$169B $38.18 0.21%
PFE icon
10
Pfizer
PFE
$159B
$159B $27.82 0.64%
BMY icon
11
Bristol-Myers Squibb
BMY
$122B
$122B $59.58 0.2%
SNY icon
12
Sanofi
SNY
$96.4B
$96.4B $40.23 0.07%
GSK icon
13
GSK
GSK
$93.2B
$93.2B $46.54 1.02%
BIIB icon
14
Biogen
BIIB
$32.3B
$32.3B $218.43 1.67%
GRFS
15
Grifois
GRFS
$5.04B
$5.04B $7.41 1.2%
OGN icon
16
Organon & Co
OGN
$3.61B
$3.61B $13.75 0.29%
LCTX icon
17
Lineage Cell Therapeutics
LCTX
$260M
$260M $1.03 8.7%
AMRN
18
Amarin Corp
AMRN
$253M
$253M $11.99 0.25%
PLX icon
19
Protalix BioTherapeutics
PLX
$218M
$218M $2.70 0.37%
ARMP icon
20
Armata Pharmaceuticals
ARMP
$144M
$144M $3.86 1.31%
SDEV
21
Stablecoin Development Corp
SDEV
$101M
$101M $1.99 28.4%
PTHS
22
Pelthos Therapeutics
PTHS
$78.5M
$78.5M $20.50 2.33%
OSTX
23
OS Therapies Inc
OSTX
$75.8M
$75.8M $1.62 4.52%
MAIA icon
24
MAIA Biotechnology
MAIA
$71M
$71M $1.15 2.54%
SER icon
25
Serina Therapeutics
SER
$51.1M
$51.1M $2.01 0%
1
2

Drug Manufacturers - General Stocks at a Glance

Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.

There are 48 Drug Manufacturers - General industry stocks tracked by Wall St. Rank, worth a combined $4.1T.

The largest by market cap are Eli Lilly (LLY) at $1.04T, Johnson & Johnson (JNJ) at $618B and AbbVie (ABBV) at $481B.

Among institutional investors, Eli Lilly (LLY) drew the most net new fund positions in Q2 2026: 417 funds opened new positions, taking total fund holders up 253 (5.8%) quarter-over-quarter.

  • Combined market cap: $4.1T across 48 stocks.
  • Largest constituent: Eli Lilly (LLY), $1.04T market cap.
  • Most net new fund positions in Q2 2026: Eli Lilly (LLY), +253 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.